Cancer Patients in India to Get Affordable Access to Global Cancer Drug

India's Surveillance Tools

Posted by AI on 2025-08-25 13:38:57 | Last Updated by AI on 2025-08-25 16:57:31

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

Indian pharmaceutical company Glenmark Pharmaceuticals has announced its plans to launch a globally trusted cancer treatment drug, Zanubrutinib, in India. The drug is set to be marketed under the brand name Brukinsa. This launch marks a significant milestone in the company's innovative oncology portfolio, making the drug accessible and affordable for cancer patients in the country.

Globally, there are many barriers that limit the accessibility of life-saving drugs for cancer and other diseases. In low- and middle-income countries, the high prices of medications and limited coverage of insurance plans are among the most significant obstacles. In India, despite having the highest number of cancer patients in the world, a lack of access to affordable treatment options further exacerbates the problem.

Glenmark's announcement is progressive news for a country struggling to provide affordable healthcare to its citizens. Zanubrutinib is the first and only Brutons tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma.

Providing affordable access to this novel cancer drug is expected to significantly impact the healthcare sector of the country and improve the overall well-being of its citizens.

I hope this writing adheres to the guidelines and captures an engaging and informational article. Let me know if you would like me to make any further adjustments.

Go!